Clinical Trials
20 trialsNCT07038343 2026-05-13
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06802835 2026-05-11
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 1/2 Recruiting
NCT05261750 2026-02-25
Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer
PT. Prodia Stem Cell Indonesia
Phase 1/2 Active not recruiting
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT05592626 2025-07-09
START-001
Marengo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT02538510 2024-11-26
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
University of Washington
Phase 1/2 Completed
NCT03813394 2024-11-22
2018/00947
National University Hospital, Singapore
Phase 1/2 Active not recruiting
NCT03769467 2024-11-14
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Atara Biotherapeutics
Phase 1/2 Terminated
NCT03682055 2023-08-15
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
Cullinan Therapeutics Inc.
Phase 1/2 Terminated
NCT05198531 2022-01-21
To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT01469429 2020-02-20
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT01806675 2019-10-03
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Stanford University
Phase 1/2 Completed
NCT03007836 2019-09-12
High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Completed
NCT02507154 2018-08-21
NKEXPHNC
National University Hospital, Singapore
Phase 1/2 Unknown
NCT02980315 2016-12-02
A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application
The Second Hospital of Nanjing Medical University
Phase 1/2 Unknown
NCT01735409 2014-01-28
ABX-DDP-Dose
Sun Yat-sen University
Phase 1/2 Unknown
NCT00003182 2013-12-04
Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00003251 2013-12-04
Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00005952 2013-06-20
Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors
Duke University
Phase 1/2 Completed
NCT00123864 2010-02-09
Study Using Intensity-modulated Radiation Therapy in Patients With Nasopharynx Cancer to Permit Sparing of Contralateral Parotid Gland Function
AHS Cancer Control Alberta
Phase 1/2 Completed